Lasa Supergenerics has accepted the resignation of Ganesh Potdar as Additional Director in the capacity of Whole Time Director. The change takes effect from the closing hours of Tuesday, August 25, 2026.

Potdar cited personal commitments as the reason for stepping down from his role. The company confirmed that there are no other material reasons for the resignation beyond those stated in his letter dated August 25, 2026.

Regulatory Disclosure

The company made the disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also adhered to the SEBI Circular dated September 9, 2015 (CIR/CFD/CMD/4/2015).

Omkar Pravin Herlekar, Chairman and Managing Director of Lasa Supergenerics, signed the intimation to the stock exchanges. The full details of the resignation are available on the company's website.

Key Details

• Resigning Director: Ganesh Potdar (DIN: 11455401)
• Designation: Additional Director in capacity of Whole Time Director
• Effective Date: Closing hours of August 25, 2026
• Reason: Personal commitments

Omkar Herlekar, a promoter of Lasa Supergenerics Limited , has confirmed that he did not create any encumbrance on shares during the financial year ended March 31, 2026. The declaration, submitted to the stock exchanges on April 7, 2026, states that no shares were pledged directly or indirectly during FY26 other than those already disclosed in previous financial years. This status indicates stability in the promoter's holding structure regarding pledged collateral during the reported period.

The disclosure was filed in compliance with Regulation 31(4) and (5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations mandate promoters to provide an annual declaration regarding the encumbrance of their shareholdings. The filing was addressed to the Corporate Services Departments of BSE Limited and National Stock Exchange of India Limited to update their records.

Key Disclosure Details

The following table summarizes the particulars of the disclosure:

The confirmation of no new encumbrances provides transparency to shareholders regarding the promoter's financial commitments and the potential risk of pledge invocation. The document was signed by Omkar Herlekar, citing his Director Identification Number (DIN) as 01587154. A copy of the disclosure was also forwarded to the members of the Audit Committee of Lasa Supergenerics Limited for their information.